IDEXX LABORATORIES INC /DE
At today's price, IDEXX LABORATORIES INC /DE (IDXX) is priced for +35.7% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• IDEXX runs a razor-and-blade model in veterinary diagnostics: it places analyzers in animal clinics, then earns high-margin recurring revenue from the consumables, test kits, and reference-lab services those instruments pull through, a stream the company calls its recurring diagnostic revenue [Source: IDEXX FY2025 10-K, accession 0000874716-26-000038]. • The quality is exceptional: a roughly 32% operating margin, a return on equity above 70%, and a balance sheet with almost no net debt, which
Is IDXX overvalued? See what's priced in →
1,277 institutional managers reported holding IDXX in 13F filings for the quarter ended 2026-03-31. Together they hold about 88% of the company; the top 10 hold 42%. 103 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 2.1M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
IDXX has cut its share count 6.7% over the past five years, spending $3.81B on repurchases. It pays no dividend. Cash returned over the past three years: $2.54B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at IDXX over the trailing three years. Absence is a fact about the company, not a signal. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
IDXX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | -6.4% | -16.6% |
| 2023-11-02 | +5.0% | +28.4% |
| 2024-02-23 | +7.6% | -13.4% |
| 2024-05-02 | -3.4% | +0.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
IDXX's latest 8-K filings: 2026-05-15 (items 5.03, 5.07, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-03-26 (items 5.02, 9.01); 2026-02-13 (items 5.02); 2026-02-02 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.